[go: up one dir, main page]

WO1990004387A3 - Composition de traitement de symptomes relatifs au manque de tabac - Google Patents

Composition de traitement de symptomes relatifs au manque de tabac Download PDF

Info

Publication number
WO1990004387A3
WO1990004387A3 PCT/US1989/004743 US8904743W WO9004387A3 WO 1990004387 A3 WO1990004387 A3 WO 1990004387A3 US 8904743 W US8904743 W US 8904743W WO 9004387 A3 WO9004387 A3 WO 9004387A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
withdrawal symptoms
treating tobacco
tobacco withdrawal
disturbances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1989/004743
Other languages
English (en)
Other versions
WO1990004387A2 (fr
Inventor
Richard J Wurtman
Judith J Wurtman
Bonnie Spring
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Priority to EP89912045A priority Critical patent/EP0440704B1/fr
Priority to DE68924537T priority patent/DE68924537T2/de
Publication of WO1990004387A2 publication Critical patent/WO1990004387A2/fr
Publication of WO1990004387A3 publication Critical patent/WO1990004387A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des compositions utiles dans le traitement de troubles de l'appétit, de l'humeur, du manque de nicotine associé et ressenti par des sujets après que ces derniers aient cessé de fumer, ainsi que des procédés d'utilisation desdites compositions. Lesdites compositions comprennent des médicaments sérotoninergiques, tels que la d-fenfluramine et la fluoxétine.
PCT/US1989/004743 1988-10-26 1989-10-25 Composition de traitement de symptomes relatifs au manque de tabac Ceased WO1990004387A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP89912045A EP0440704B1 (fr) 1988-10-26 1989-10-25 Composition de traitement de symptomes relatifs au manque de tabac
DE68924537T DE68924537T2 (de) 1988-10-26 1989-10-25 Zusammensetzung zur behandlung der symptome verursacht durch beseitigung von tabak.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/262,625 US4999382A (en) 1988-10-26 1988-10-26 Compositions for treating tobacco withdrawal symptoms and methods for their use
US262,625 1988-10-26

Publications (2)

Publication Number Publication Date
WO1990004387A2 WO1990004387A2 (fr) 1990-05-03
WO1990004387A3 true WO1990004387A3 (fr) 1990-06-28

Family

ID=22998317

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/004743 Ceased WO1990004387A2 (fr) 1988-10-26 1989-10-25 Composition de traitement de symptomes relatifs au manque de tabac

Country Status (7)

Country Link
US (1) US4999382A (fr)
EP (1) EP0440704B1 (fr)
JP (1) JP2997280B2 (fr)
AT (1) ATE128864T1 (fr)
CA (1) CA2001572C (fr)
DE (1) DE68924537T2 (fr)
WO (1) WO1990004387A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0415612B1 (fr) * 1989-08-30 1993-11-10 Pfizer Inc. Utilisation de la sertraline pour le traitement des dépendances aux produits chimiques
US5455254A (en) * 1991-02-15 1995-10-03 Mondadori; Cesare Substituted benzofuranylpiperidine as a nootropic agent
DK36391D0 (da) * 1991-03-01 1991-03-01 Lundbeck & Co As H Anvendelse af piperidylsubstituerede indolderivater til behandling af stofmisbrug
BE1005200A3 (fr) * 1991-08-27 1993-05-25 Vandendael Kathleen Mariette Utilisation de tryptophane et composition nutritionnelle comprenant du tryptophane.
AU2446895A (en) * 1994-04-22 1995-11-16 Assistance Publique - Hopitaux De Paris Use of mao-a inhibitors for the manufacture of a medicament in the treatment of tobacco withdrawal symptoms in smokers
US6004990A (en) * 1994-06-03 1999-12-21 Zebra Pharmaceuticals Meta substituted arylalkylamines and therapeutic and diagnostic uses therefor
ES2157330T3 (es) * 1994-06-03 2001-08-16 Thejmde Trust Composicion que comprende aril-alquil-amina meta substituida, usos terapeuticos y diagnosticos.
BR9501972A (pt) * 1995-05-09 1997-08-26 Tostes Luiz Roberto Mallat Composição farmacêutica metodo para tratamento de dependência ou abuso de álcool e método para tratamento de distúrbios psiquiátricos geneticamente relacionados ao alcoolismo
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
CA2223588C (fr) * 1995-06-07 2004-01-06 Noven Pharmaceuticals, Inc. Compositions transdermiques contenant des medicaments de faible poids moleculaire liquides a temperature ambiante
US6512010B1 (en) * 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US6166032A (en) * 1997-02-07 2000-12-26 Synapse Pharmaceuticals International, Inc. Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
US5760049A (en) * 1997-02-21 1998-06-02 Synapse Pharmaceuticals International, Inc. Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
US6908631B1 (en) 1997-12-01 2005-06-21 Nicogen, Inc. Therapeutic and diagnostic methods dependent on CYP2A enzymes
US6333357B1 (en) * 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
US6617361B2 (en) 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
ES2425114T3 (es) * 2000-03-16 2013-10-11 The Mclean Hospital Corporation CDP-colina y uridina para el tratamiento del abuso del acohol
MXPA03001472A (es) * 2000-08-16 2003-06-06 Upjohn Co Compuestos para el tratamiento de trastornos adictivos.
AU2003291368A1 (en) * 2002-11-08 2004-06-03 The Mclean Hospital Corporation Compounds for the treatment of tobacco dependence and withdrawal
WO2005034874A2 (fr) * 2003-10-08 2005-04-21 The Mclean Hospital Corporation Efficacite amelioree d'une therapie aux acides gras omega-3 dans le traitement de troubles psychiatriques et d'autres indications
JP2007508315A (ja) * 2003-10-08 2007-04-05 ザ マクレーン ホスピタル コーポレーション ω−３脂肪酸を含む組み合わせを用いて、精神障害、物質乱用障害、および他の障害を治療する方法
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
EP1765075A4 (fr) * 2004-06-10 2010-11-10 Mclean Hospital Corp Pyrimidines, notamment de l'uridine, utilisees dans des traitements sur des patients atteints de troubles bipolaires
EP1765364A4 (fr) * 2004-06-10 2010-09-22 Mclean Hospital Corp Pyrimidines, tels que cytidine, dans les traitements de patients souffrant de troubles bipolaires
EP1784199A4 (fr) * 2004-08-11 2010-06-23 Mclean Hospital Corp Compose pour le traitement de la dependance, de la suppression et de l'usage de la marijuana
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
CA3130580A1 (fr) 2019-02-17 2020-08-20 Neurawell Therapeutics Compositions et methodes pour le traitement de la depression et d'autres troubles

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0153083A2 (fr) * 1984-02-06 1985-08-28 Eli Lilly And Company -4,Dialkylaminotetrahydrobenz[c,d]indoles substitués en position 6-
WO1988003801A1 (fr) * 1986-11-21 1988-06-02 Glaxo Group Limited Medicaments pour le traitement ou la prevention d'un syndrome de reaction a la privation
EP0302008A2 (fr) * 1987-07-11 1989-02-01 Sandoz Ag Antagonistes de 5HT-3 pour la prévention de dépendance
EP0314984A2 (fr) * 1987-10-31 1989-05-10 Troponwerke GmbH &amp; Co. KG Application des dérivés de la 2-pyrimidinyl-1-pipérazine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2129299A (en) 1982-11-09 1984-05-16 Alec James Coppen Pharmaceutical compositions
US4650789A (en) 1985-10-15 1987-03-17 Commonwealth Medical Corporation Of America Method and composition for increasing production of serotonin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0153083A2 (fr) * 1984-02-06 1985-08-28 Eli Lilly And Company -4,Dialkylaminotetrahydrobenz[c,d]indoles substitués en position 6-
WO1988003801A1 (fr) * 1986-11-21 1988-06-02 Glaxo Group Limited Medicaments pour le traitement ou la prevention d'un syndrome de reaction a la privation
EP0302008A2 (fr) * 1987-07-11 1989-02-01 Sandoz Ag Antagonistes de 5HT-3 pour la prévention de dépendance
EP0314984A2 (fr) * 1987-10-31 1989-05-10 Troponwerke GmbH &amp; Co. KG Application des dérivés de la 2-pyrimidinyl-1-pipérazine

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
Am. J. Psychiatry, Volume 146, No. 3, March 1989, American Psychiatric Association, N.B. EDWARDS et al.: "Doxepin as an Adjunct to Smoking Cessation: a Double-Blind Pilot Study", pages 373-376 see the whole article, with Emphasis on page 375, left-hand column, lines 8-19 *
Am. J. Psychiatry, Volume 146, No. 9, September 1989 C.M. CHURCHILL et al.: "Antidepressants and Cessation of Smoking", pages 1238-1239 see the whole letter *
Arch. Gen. Psychiatry, Volume 46, No. 3, March 1989, F. GAWIN: "Buspirone Reduces Smoking", pages 288-289 see the whole letter *
Br. J. Pharmacol., Volume 41, No. 2, February 1971, G.L.S. PAWAN et al.: "Preliminary Study on the Effects of Fenfluramine Derivative, 'S992' in Man", pages 416P-417P see page 417P, paragraph 1 *
Can. Med. Assoc. J., Volume 107, No. 8, 21 October 1972, E. WONG: "Effect of Surmontil on the Cigarette Habit", page 727 see the whole letter *
Clin. Pharmacol. Ther., Volume 46, No. 3, September 1989, C.A. NARANJO et al.: "Differential effects of Viqualine on Alcohol Intake and Other Consummatory Behaviors", pages 301-306 see summary *
International Journal of Obesity, Volume 6, No. 4, 1982, P. TURNER et al.: "The Peripheral Actions of Antiobesity Drugs", pages 411-415 see page 412, lines 1-3 *
J. Clin. Psychopharmacol., Volume 7, No. 6, December 1987, E.M. SELLERS et al.: "Do Serotonin Uptake Inhibitors Decrease Smoking? Observations in a Group of Heavy Drinkers", pages 417-420 see the title *
Molecular Pharmacology, Volume 33, No. 3, March 1988, The American Society for Pharmacology and Experimental Therapeutics, D. HOYER et al.: "Identification of Serotonin 5-HT3 Recognition Sites in Membranes of N1E-115 Neuroblastoma Cells by Radioligand Binding", pages 303-309 see summary *
Munch. Med. Wochenschr., Volume 112, No. 51, 18 December 1970, B. LUBAN-PLOZZA: "Das Rauchen und die Moglichkeiten der Raucher-Ent-Wohnung", pages 2322-2327 see summary; page 2325, left-hand column, lines 15-22; page 2326, right-hand column; page 2327, left-hand column *
Psychosom. Med., Volume 33, No. 6, November-December 1971, M.A. JACOBS et al.: "Interaction of Personality and Treatment Conditions Associated with Success in a Smoking Control Program", pages 545-556 see page 546, right-hand column, lines 15-35; page 547, left-hand column; page 548, table 1; page 549, table 2 *
Psychosomatics, Volume 29, No. 2, Spring 1988, The Academy of Psychosomatic Medicine, N.B. EDWARDS et al.: "Doxepin in the Treatment of Nicotine Withdrawal", pages 203-206 see Abstract *

Also Published As

Publication number Publication date
JPH04501413A (ja) 1992-03-12
EP0440704A1 (fr) 1991-08-14
EP0440704B1 (fr) 1995-10-11
CA2001572C (fr) 2001-01-02
JP2997280B2 (ja) 2000-01-11
US4999382A (en) 1991-03-12
DE68924537D1 (de) 1995-11-16
DE68924537T2 (de) 1996-08-01
CA2001572A1 (fr) 1990-04-26
ATE128864T1 (de) 1995-10-15
WO1990004387A2 (fr) 1990-05-03

Similar Documents

Publication Publication Date Title
WO1990004387A3 (fr) Composition de traitement de symptomes relatifs au manque de tabac
HUP0001153A2 (hu) Kémiailag módosított polipeptidek, eljárás ezek előállítására, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
IL114128A0 (en) Composition for the treatment of nicotine craving and/or smoking withdrawal symptoms
DK1056856T3 (da) Modificeret ciliarneurotrofisk faktor samt fremgangsmåder til dannelse og anvendelse deraf
HUT74004A (en) Inhibitors of beta-amyloid protein production
GR3029335T3 (en) Method of preparing a radioactive rhenium complex solution.
ATE232384T1 (de) Zusammensetzungen zur behandlung von nikotinabhängigkeit, enthaltend mecamylamin und bupropion
EA199700119A1 (ru) Соединения, оказывающие эффекты на системы, связанные с серотонином
ZA975866B (en) Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases.
IL118269A0 (en) Tetralin derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
EG18730A (en) Substituted tetralin, chromans and related compounds in the treatment of asthma, arthritis and related diseases
DE3856295D1 (de) Behandlung des prämenstruellen oder späten lutealsphase-syndroms
DK217588A (da) 17beta-(cyclopropylamino)-androst-5-en-3beta-olderivater, deres fremstilling og anvendelse som laegemidler
SE9603725D0 (sv) New teatment
EP0369685A3 (fr) Analogue de fluoxétine
DK541189A (da) Anvendelse af nalmefen eller naltrexon til fremstilling af et laegemiddel til behandling af interstitiel cystitis
ATE307203T1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
IL114130A0 (en) Composition for the treatment of nicotine craving and/or smoking withdrawal symptoms
IT8719763A0 (it) Analoghi retro-inversi della timopentina e dei suoi frammenti, il metodo per la loro sintesi ed il loro impiego per la preparazionedi composizioni farmaceutiche.
EP0318233A3 (fr) Inhibiteurs d&#39;assimilation de sérotonine et de norépinéphrine
ES483661A1 (es) Procedimiento para la obtencion de derivados de 1,4-dihidro-piridina sila-sustituidos
MY120530A (en) Combination preparation for use in dementia
EP0304294A3 (fr) Taliscanine et autres aristolactames pour le traitement des maladies neurologiques, maladie de Parkinson, maladie d&#39;Alzheimer et de l&#39;impuissance
HU9201799D0 (en) New 2-amino-5-ciano-1,4-dihydropiridine-derivatives, process for their use and their use as medicaments
CA2002182A1 (fr) Compositions pour le traitement du syndrome premenstruel ou de la phase luteinique tardive, et leur mode d&#39;emploi

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1989912045

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1989912045

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1989912045

Country of ref document: EP